利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.029 秒)

    Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection agents
    3.
    发明授权
    Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection agents 失效
    用于检测进行性慢性痴呆疾病的方法及相应的肽和检测剂

    公开(公告)号：US07202044B2

    公开(公告)日：2007-04-10

    申请号：US10476976

    申请日：2002-05-08

    申请人： Norbert Lamping ,  Hans-Dieter Zucht ,  Harmut Selle ,  Michael Jürgens ,  Gabriele Heine ,  Rüdiger Hess

    发明人： Norbert Lamping ,  Hans-Dieter Zucht ,  Harmut Selle ,  Michael Jürgens ,  Gabriele Heine ,  Rüdiger Hess

    IPC分类号： G01N33/53 ,  G01N33/567 ,  G01N33/536 ,  A61K38/28 ,  C07K5/00 ,  C07K14/00

    CPC分类号： C07K14/52 ,  A61K38/00 ,  G01N33/6896 ,  G01N2500/00 ,  G01N2800/2814

    摘要： The invention relates to defined peptides and the quantitative determination thereof in body fluids of patients suffering from progredient chronic dementia, in relation to the concentration of said peptides in a control group. The inventive peptides come from a protein precursor having the corresponding gene, are processed in a specific manner, and are optionally post-translationally modified, especially phosphorylized. An increase in the concentrations of these peptides or the corresponding non-processed protein indicates progredient chronic dementia. Progredient chronic dementia is detected by identifying the peptides and/or the protein individually or in combinations. The invention also relates to the use of said peptides for controlling the course of progredient chronic dementia and for the prognosis of progredient chronic dementia, especially for complementing or replacing mini-mental scores, and for developing therapeutic agents to combat progredient chronic dementia such as Alzheimer's disease.

    摘要翻译： 本发明涉及定义的肽及其在患有慢性痴呆症的患者的体液中的定量测定，与所述肽在对照组中的浓度有关。 本发明的肽来自具有相应基因的蛋白质前体，以特定方式加工，并且任选地经翻译后修饰，特别是磷酸化。 这些肽或相应的未加工蛋白质的浓度的增加表示慢性痴呆。 通过单独或组合地鉴定肽和/或蛋白质来检测慢性痴呆。 本发明还涉及所述肽用于控制慢性痴呆进展过程以及慢性痴呆进展的预后，特别是用于补充或替代迷你精神分数，以及用于开发治疗剂以对抗慢性痴呆，如阿尔茨海默病 疾病。

    Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection reagents
    4.
    发明申请
    Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection reagents 审中-公开
    用于检测进行性慢性痴呆疾病的方法，以及相应的肽和检测试剂

    公开(公告)号：US20070031908A1

    公开(公告)日：2007-02-08

    申请号：US10549141

    申请日：2004-03-18

    申请人： Norbert Lamping ,  Hans Zucht ,  Hartmut Selle ,  Michael Jurgens ,  Gabriele Heine ,  Rudiger Hess ,  Markus Kellmann ,  Jens Lamerz ,  Thomas Mohring

    发明人： Norbert Lamping ,  Hans Zucht ,  Hartmut Selle ,  Michael Jurgens ,  Gabriele Heine ,  Rudiger Hess ,  Markus Kellmann ,  Jens Lamerz ,  Thomas Mohring

    IPC分类号： G01N33/543

    CPC分类号： C07K14/4711 ,  G01N33/6896 ,  G01N33/9406 ,  G01N2800/2821

    摘要： The invention relates to a method for detecting progressive, chronic dementia diseases or a predisposition to such diseases or method for the prognosis of such diseases. For this purpose, the concentration of particular peptides in body fluids or other samples from the patient is measured in a method which can be carried out in a laboratory. The invention further relates to peptides which have been found for determining the presence and/or the grade of the progressive, chronic dementia disease. The invention additionally relates to detection reagents such as antibodies and nucleic acids and the like for detecting said peptides or the corresponding nucleic acids. The invention further relates to pharmaceutical products which comprise the peptides according to the present invention, antibodies directed to said peptides, nucleic acids corresponding to said peptides, peptide antagonists, or peptide agonists for the therapy, diagnosis, prognosis or prophylaxis of neurological diseases, in particular of Alzheimer's disease. The invention further relates to methods for stratifying patients or participants in clinical studies.

    摘要翻译： 本发明涉及一种用于检测进行性慢性痴呆疾病或倾向于这些疾病或这种疾病预后的方法。 为此目的，以可以在实验室中进行的方法测量体液或来自患者的其它样品中特定肽的浓度。 本发明还涉及已经发现用于确定进行性慢性痴呆疾病的存在和/或等级的肽。 本发明还涉及用于检测所述肽或相应核酸的检测试剂，例如抗体和核酸等。 本发明还涉及包含根据本发明的肽的药物产品，针对所述肽的抗体，对应于所述肽的核酸，肽拮抗剂或肽激动剂，用于治疗，诊断，预后或预防神经疾病， 特别是阿尔茨海默病。 本发明还涉及用于分层临床研究中的患者或参与者的方法。

    Tif1-Beta Peptides and Nucleic Acids for Diagnosis and Therapy of Cancer and Colorectal Cancerous Disorders
    5.
    发明申请
    Tif1-Beta Peptides and Nucleic Acids for Diagnosis and Therapy of Cancer and Colorectal Cancerous Disorders 审中-公开
    Tif1-β肽和核酸用于癌症和结肠直肠癌的诊断和治疗

    公开(公告)号：US20080118929A1

    公开(公告)日：2008-05-22

    申请号：US11883133

    申请日：2006-01-24

    申请人： Harald Tammen ,  Rudiger Hess ,  Karl Schorn ,  Rudolf Reiter ,  Susanne Neitz ,  Norbert Lamping

    发明人： Harald Tammen ,  Rudiger Hess ,  Karl Schorn ,  Rudolf Reiter ,  Susanne Neitz ,  Norbert Lamping

    IPC分类号： G01N33/574 ,  C07K14/00 ,  C07K16/18 ,  C12N15/11 ,  C12N15/00 ,  C12N5/06 ,  C12Q1/68

    CPC分类号： G01N33/57419

    摘要： Many disorders, especially neoplastic disorders such as cancer and polyps, are the result of hyperproliferative cells or of cells with differentiation disorders. For these types of disorders early detection is of pivotal importance and reliable and early biomarkers for common types of cancers such as colorectal cancer are still not available. Thus, there is a need for new markers and for methods for identifying such new markers. The invention provides peptides and proteins and derivatives thereof originating from transcription intermediary factor-1 beta (TIF1-beta) suitable as markers and therapeutics for disorders such as cancer, preferably colorectal cancerous or related disorders such as polyps.

    摘要翻译： 许多疾病，特别是肿瘤性疾病如癌症和息肉，是过度增殖细胞或具有分化障碍的细胞的结果。 对于这些类型的疾病，早期检测是至关重要的，并且常见类型的癌症如结肠直肠癌的可靠和早期生物标志物仍然不可用。 因此，需要新的标记和用于鉴定这种新标记的方法。 本发明提供源自转录中介因子-1β（TIF1-β）的肽和蛋白质及其衍生物，其适用于诸如癌症，优选结肠直肠癌或相关疾病如息肉的疾病的标记物和治疗剂。